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Abstract 
Preparation and characterization of 2,6-diacetylpyridine bis(
4
N-p-
chlorophenylthiosemicarbazone) ligand, H2L, and its palladium(II) and platinum(II) 
complexes [PdL] and [PtL], is described. The molecular structure of the two new 
complexes has been determined by single crystal X-ray diffraction. The ligand act as 
dianionic tetradentate donor coordinating to the metal center in a square planar 
geometry through the pyridine nitrogen atom and the azomethine nitrogen and thione 
sulfur atoms from one thiosemicarbazone arm, the fourth coordination position is 
occupied by the hydrazine nitrogen atom of the other arm. New free ligand and its metal 
complexes have been evaluated for antiproliferative activity in vitro against NCI-H460, 
T-47D, A2780 and A2780cisR human cancer cell lines. The cytotoxicity data suggest 
that these compounds may be endowed with important antitumor properties, especially 
H2L and [PtL] since they are capable of not only circumvent cisplatin resistance in 
A2780cisR cells but also exhibit high antiproliferative activity in breast cancer T-47D 
cells. The interaction of H2L with calf thymus DNA was also investigated and its 
binding constant (Kb) determined. 
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1. Introduction 
Platinum metallo-drugs are among the most effective agents for the treatment of cancer 
however its clinical utility is restricted due to the frequent development of drug 
resistance, the limited spectrum of tumors against which these drugs are active and also 
the severe normal tissue toxicity [1-5]. These disadvantages have driven the 
development of improved platinum-based anticancer drugs whose structure and mode of 
action differ from that of cisplatin, especially those that interact with specific molecular 
targets as for example are the processes associated to DNA: transcription, replication 
and repair [6-9].  
In this regard, of particular interest are compounds targeting ribonucleotide 
reductase (RR), enzyme that catalyzes the reduction of ribonucleotides to 
deoxyribonucleotides and provides the building blocks for the de novo DNA synthesis 
in all living cells. Cancer cells require increased RR activity to meet the demand for 
deoxyribonucleotides that are needed to support their rapid proliferation. Thus 
inhibition of RR activity leads to inhibition of DNA synthesis and repair, and also 
induces cell cycle arrest and apoptosis [10-12].  
α-(N)-heterocyclic thiosemicarbazones, (N)-TSCs, have been reported to be 
among the most effective RR inhibitors yet identified and many efforts have been 
devoted to the study of the structure–activity relationship of thiosemicarbazone 
derivatives. The anticancer activity of (N)-TSCs is closely related to the nature of the 
heterocyclic ring of the parent aldehyde or ketone, metal chelation ability and terminal 
amino substitution [13-20]. In this sense pyridine ring itself is a part of many natural 
and synthetically prepared pharmaceuticals and moreover it plays a significant role in 
many biological processes like nicotinamide adenine dinucleotide phosphate NADP or 
the important vitamins niacin and pyridoxine (vitamins B3 and B6) [21, 22].  
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Keeping in view the above observations and as part of our systematic 
investigation on the coordination chemistry of thiosemicarbazone derivatives we 
recently reported palladium(II) and platinum(II) complexes derived of 2,6-
diacetylpyridine bis(
4
N-o-tolylthiosemicarbazone) and 2,6-diacetylpyridine bis(
4
N-p-
tolylthiosemicarbazone)
 
ligands. The in vitro antitumor studies have shown that these 
complexes exhibit important antiproliferative activity in A2780 and A2780cisR human 
cancer cell lines and these results encouraged us to further investigate their cytotoxic 
properties as well as those of novel derivatives [23].  
This work is aimed to determine if the presence of an aryl ring with an electron 
withdrawing substituent (such as p-chlorophenyl group) results beneficial for the 
antitumor activity of bis(
4
N-subtituted thiosemicarbazones) ligands derived from 2,6-
diacetylpyridine. Therefore here we describe the synthesis and chemical 
characterization of the new 2,6-diacetylpyridine bis(
4
N-p- 
chlorophenylthiosemicarbazone) ligand, H2L, (Scheme 1) and its palladium(II) and 
platinum(II) complexes, [PdL] and [PtL].  
 
Insert Scheme 1 
 
The cytotoxic activity of the new compounds synthesized and cisplatin (assumed 
as the reference antitumor drug) against four human cancer cell lines: NCI-H460 (non-
small cell lung cancer), T-47D (breast cancer), A2780 and A2780cisR (epithelial 
ovarian cancer) has been studied. The interaction of H2L with calf thymus DNA (CT-
DNA) was also investigated and its binding constant (Kb) determined. 
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2. Experimental 
2.1. Measurements 
Elemental analyses were performed on a LECO CHNS-932 microanalyzer. Fast 
atom bombardment (FAB) mass spectra (MS) were performed on a VG AutoSpec 
spectrometer. 
1
H NMR spectra were recorded on Bruker AMX-300 spectrometer. All 
cited physical measurements were obtained out by the Servicio Interdepartamental de 
Investigación (SIdI) of the Universidad Autónoma de Madrid. 
Melting points were determined with a Stuart Scientific SMP3 apparatus. 
Infrared spectra were recorded on a Bomen–Michelson spectrophotometer. 13C NMR 
spectra were recorded on a 400 Advance Bruker Fourier Transform spectrometer. 
Electronic spectra were recorded on a Thermo Scientific Evolution 260 Bio UV-visible 
(UV-VIS) spectrophotometer.  
2.2. Materials 
Solvents were purified and dried according to standard procedures. Hydrazine 
hydrate, 2,6-diacetylpyridine, p-chlorophenyl isothiocyanate, PdCl2(PPh3)2 and 
PtCl2(PPh3)2 were commercially available.    
2.3. Synthesis of compounds 
2,6-Diacetylpyridine bis(
4
N-p-chlorophenylthiosemicarbazone), H2L. An ethanolic 
solution of hydrazine hydrate (0.250 g, 5 mmol) was added dropwise with constant 
stirring to an ethanolic solution of p-chlorophenyl isothiocyanate (0.848 g, 5 mmol). 
The reaction mixture was stirred for one more hour and then the white product p-
chlorophenylthiosemicarbazide formed was filtered, washed with cold ethanol and 
diethyl ether, dried in vacuo and recrystallized from ethanol. An ethanolic solution of 
the p-chlorophenylthiosemicarbazide (0.402 g, 2 mmol) was then stirred with 2,6-
diacetylpyridine (0.163 g, 1 mmol) for 5 h. The resulting solution was reduced to half 
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volume and the pale yellow solid formed was filtered, washed with ethanol, diethyl 
ether and finally dried in vacuo. 
Yield (80%), mp 220 ºC (decomposes). Elemental analysis found, C, 52.20; H, 4.25; N, 
18.00; S, 12.20; C23H21N7S2Cl2 requires C, 52.07; H, 3.99, N, 18.48; S, 12.09 %. MS 
(FAB
+
 with mNBA: nitrobenzyl alcohol matrix) m/z 530.0 for [H2L+H]
+
. IR (KBr 
pellet): υ/cm-1 3335, 3306, 3210 (w, NH); 1588 (s, CN); 827, 809 (w, CS-thioamide 
IV); 585 (pyridine ring). 
1
H NMR (d
6
-DMSO, ppm), δ=10.80 [s, 2NH, 2H]; 10.20 [s, 
4
NH, 2H]; 8.55 [d, J=7.9 Hz, CH-pyridine, 2H]; 7.85 [t, J=7.9 Hz, CH-pyridine, 1H]; 
7.60 (d, J=8.7 Hz, aromatic-thiosemicarbazide, 4H); 7.45 (d, J=8.7 Hz, aromatic-
thiosemicarbazide, 4H); 2.50 (s, CH3-diacetylpyridine, 6H). 
13
C NMR (d
6
-DMSO, 
ppm), δ=178.3 (C=S); 153.78 (C2,C6-pyridine); 149.85 (C=1N); 138.54 (C4-pyridine); 
137.17 (C3,C5-pyridine); 130.08 (aromatic-thiosemicarbazide); 128.49 (aromatic-
thiosemicarbazide); 128.34 (aromatic-thiosemicarbazide); 127.37 (aromatic-
thiosemicarbazide); 121.96 (aromatic-thiosemicarbazide); 12.98 (CH3-diacetylpyridine). 
UV/VIS (DMSO): λ/nm 250, 337. 
2,6-Diacetylpyridine bis(
4
N-p-chlorophenylthiosemicarbazonato)palladium(II), 
[PdL]. The reaction of H2L ligand with PdCl2(PPh3)2, in toluene, in presence of Et3N, in 
1:1 molar ratios over 20 h at room temperature led to the formation of an orange 
solution which was filtered and left to stand at ambient temperature for two days. The 
brown solid formed was filtered, washed several times with hot water, diethyl ether and 
finally dried in vacuo. 
Yield (55%), mp >250 ºC. Elemental analysis found, C, 43.35; H, 3.35, N, 15.10; S, 
10.05; C23H19N7S2Cl2Pd requires C, 43.51; H, 3.02, N, 15.44; S, 10.10 %. MS (FAB
+
 
with mNBA matrix) m/z 636 for [PdL+H]
+
. IR (KBr pellet): υ/cm-1 3243 (s, NH); 1595 
(s, CN); 830, 804 (vw) (CS-thioamide IV); 603 (pyridine ring). 
1
H NMR (300 MHz, d
6
-
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DMSO, ppm), δ=10.75, 10.18 [s, 4NH, 2H]; 8.43-8.10 [m, CH-pyridine, 3H]; 7.71-7.34 
(m, aromatic-thiosemicarbazide, 8H); 2.72, 2.62 (s, CH3-diacetylpyridine, 6H). UV/VIS 
(DMSO): λ/nm 267, 340, 410, 470. 
Recrystallization from DMSO led to the isolation of orange crystals of [PdL]·DMSO 
that were suitable for X-ray-diffraction. 
2,6-Diacetylpyridine bis(
4
N-p-chlorophenylthiosemicarbazonato)platinum(II), 
[PtL]. It was prepared by the same procedure as described for [PdL] by reaction of H2L 
with PtCl2(PPh3)2 and afforded a brown solid. 
 Yield (35%), mp 192 ºC (decomposes). Elemental analysis found, C, 37.90; H, 2.55, N, 
13.60; S, 8.60; C23H19N7S2Cl2Pt requires C, 38.18; H, 2.65, N, 13.55; S, 8.86 %. MS 
(FAB
+
 with mNBA matrix) m/z 724 for [PtL+H]
+
. IR (KBr pellet): υ/cm-1 3288, 3208 
(s, NH); 1590 (s, CN); 826, 809 (vw) (CS-thioamide IV); 591 (pyridine ring). 
1
H NMR 
(300 MHz, d
6
-DMSO, ppm), δ=11.00, 10.30 [s, 4NH, 2H]; δ=8.56-8.10 [m, CH-
pyridine, 3H]; δ=7.76-7.70 (m, aromatic-thiosemicarbazide, 8H); δ=2.78, 2.71 (s, CH3-
diacetylpyridine, 6H). UV/VIS (DMSO): λ/nm 249, 267, 366. 
Recrystallization from DMSO led to the isolation of orange crystals of [PtL]·DMSO 
that were suitable for X-ray-diffraction. 
2.4. Crystallography 
Data were collected on a Bruker X8 APEX II CCD.  Crystallographic data and 
selected interatomic distances and angles are listed in Table 1. For all compounds, the 
software package SHELXTL was used for space group determination, structure 
solution, and refinement [24]. The structures were solved by direct methods, completed 
with difference Fourier syntheses, and refined with anisotropic displacement 
parameters. 
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CCDC 981268 and 981269 contain the supplementary crystallographic data for 
compounds [PdL] and [PtL] respectively. These data can be obtained free of charge at 
www.ccdc.cam.ac.uk/conts/retrieving.html [or from the Cambridge Crystallographic 
Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44-1223/336-033; e-
mail: deposit@ccdc.cam.ac.uk]. 
2.5. In vitro antiproliferative activity 
The human cancer cells: A2780 and A2780cisR (epithelial ovarian cancer), T-
47D (breast cancer) and NCI-H460  (non-small cell lung cancer); were grown in RPMI-
1640 medium supplemented with 10% foetal bovine serum (FBS) and 2 mM L-
glutamine in an atmosphere of 5% CO2 at 37 °C.  
Cell proliferation was evaluated by the sulforhodamine B assay. Cells were 
plated in 96-well sterile plates at a density of 1.5x10
4
 (for NCI-H460), 4x10
3
 (for 
A2780 and A2780cisR) or 5x10
3
 (for T-47D) cells per well with 100μL of medium and 
were then incubated for 24 h (A2780, A2780cisR and NCI-H460) or 48 h (T-47D). 
After attachment to the culture surface the cells were incubated with various 
concentrations of the compounds tested freshly dissolved in DMSO (1 mg/mL) and 
diluted in the culture medium (DMSO final concentration 1%) for 48 h (for NCI-H460) 
or 96 h (for A2780, A2780cisR and T-47D). The cells were fixed by adding 50 μL of 
30% trichloroacetic acid (TCA) per well.  
The plates were incubated at 4 °C for 1 h and then washed five times with 
distilled water. The cellular material fixed with TCA was stained with 0.4% 
sulforhodamine B dissolved in 1% acetic acid for 10 min. Unbound dye was removed 
by rinsing with 0.1% acetic acid. The protein-bound dye was extracted with 10 mM 
unbuffered Tris base for determination of optical density (at 515 nm) in a Tecan Ultra 
Evolution spectrophotometer. 
9 
 
The effects of compounds were expressed as corrected percentage inhibition 
values according to the following equation: 
 
% inhibition = [1−(T/C)] × 100 
where T is the mean absorbance of the treated cells and C the mean absorbance in the 
controls. 
The inhibitory potential of compounds was measured by calculating 
concentration–percentage inhibition curves, these curves were adjusted to the following 
equation: 
E = Emax / [1+(IC50/C)
n
] 
where E is the percentage inhibition observed, Emax is the maximal effects, IC50 is the 
concentration that inhibits 50% of maximal growth, C is the concentration of 
compounds tested and n is the slope of the semi-logarithmic dose–response sigmoid 
curves. This non-linear fitting was performed using GraphPad Prism software [25].  
For comparison purposes, the antiproliferative activity of cisplatin was evaluated 
under the same experimental conditions. All compounds were tested in two independent 
studies with triplicate points. These experiments were carried out at the Unidad de 
Evaluación de Actividades Farmacológicas de Compuestos Químicos (USEF), 
Universidad de Santiago de Compostela. 
2.6. DNA-Binding Experiments 
  Calf thymus DNA (CT-DNA) stock solution was prepared by dissolving the 
lyophilized sodium salt in Tris-buffer (NaCl 50 mM, Tris-HCl 5 mM, pH was adjusted 
to 7.2 with NaOH 0.5 M) by stirring for 5 hours. The CT-DNA solution was 
standardized spectrophotometrically [26] by using its known molar absorption 
coefficient at 260 nm (6600 M
-1
·cm
-1
). The ratio of UV absorbance at 260 and 280 nm, 
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A260/A280, of ca. 1.9, indicating that the DNA was sufficiently free of protein. Stock 
solution was kept frozen until the day of the experiment. 
 Concentrated stock solutions (5x10
-3
 M and 5x10
-5
 M) of H2L were prepared 
dissolving the compound in DMSO. From these stock solutions, for all experiments the 
desired concentration of compound was achieved by dilution with Tris-buffer (NaCl 50 
mM, Tris-HCl 5 mM, pH was adjusted to 7.2 with NaOH 0.5 M) to give homogeneous 
solutions with DMSO content of less than 2.5 %. 
  To investigate the binding mode, spectrophotometric titrations were performed 
at a ﬁxed DNA concentration equal to 1.7x10-4 M with increasing concentration of H2L 
(0-125 M) and monitoring the absorbance change at the wavelength maximum 260 nm 
after incubation (10 min. at 37ºC). 
  To calculate the binding parameters, the spectrophotometric titrations were 
performed with increasing concentration of DNA (0-40 M) at a ﬁxed compound 
concentration equal to 50
 M and monitoring the absorbance change in one  
characteristic charge transference band of the compound after incubation (10 min. at 
37ºC). 
 
3. Results and discussion 
3.1.  Synthesis and spectroscopic characterization 
  A new 2,6-diacetylpyridine bis(
4
N-monosubstituted thiosemicarbazone) ligand 
has been synthesized with high purities and acceptable yields. The yellow compound 
obtained is stable to air and moisture and was characterized by elemental analysis, 
FAB
+
 spectrometry and IR and NMR (
1
H and 
13
C) spectroscopy.  
Reaction of 2,6-diacetylpyridine bis(
4
N-p-chlorophenylthiosemicarbazone) 
ligand with equimolar amount of  MCl2(PPh3)2, where M = Pd(II) or Pt(II), led to the 
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isolation of neutral mononuclear complexes [PdL] and [PtL] in which the 
bis(thiosemicarbazone) behaves as dianionic ligand with deprotonation of hydrazine 
(
2
NH) protons and [NNNS] donor set.  
Both complexes were characterized by routine analytical and spectroscopic 
techniques. Analytical data are consistent with the formulation given, thus the FAB
+
 
mass spectra exhibited a very weak ion at m/z = 636 for [PdL] and m/z = 724 for [PtL] 
which corresponded to the predicted molecular weight of the [M+H]
+
 ions and 
moreover the isotopic patterns of this signal fit well with the theoretical isotopic 
distributions. 
The significant IR vibrational bands and the 
1
H chemical shift values of the free 
ligand and its complexes are listed in the Experimental section and Scheme 1 shows the 
numbered structure of the free ligand. As the X-ray study has shown, during metal 
complexation, the ligand behaves as a tetradentate dianionic forming two five-
membered and one six-membered chelate rings around the metal center. The high 
delocalization and the asymmetric coordination hinder the IR analysis. The stretching 
vibration υ(C=N) and the in-plane pyridine deformation bands are slightly shifted to 
higher wavenumbers which are consistent with the implication of imine and pyridine 
nitrogen atoms in the coordination however this induces only minor changes in υ(C=S) 
thioamide IV band which decreases slightly in intensity. 
In the 
1
H NMR spectrum of the double-armed H2L ligand, two independent 
singlets at δ = 10.80 and 10.20 ppm are observed for >C=N-2NH- and –C(S)-4NH- 
protons respectively. A doublet at δ = 8.55 ppm and a triplet at δ = 7.85 ppm are 
assigned to pyridyl ring protons. Aromatic p-chlorophenyl protons appear as a multiplet 
at δ = 7.60-7.45 ppm and a sharp singlet at δ = 2.50 is assigned to the methyl protons.  
In [PdL] and [PtL] complexes, the anionic coordination of the ligand is evidenced by 
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the disappearance of the signal corresponding to the >C=N-
2
NH- protons. On the other 
hand, the –C(S)-4NH- protons appear two independent signals (10.75 and 10.18 ppm for 
[PdL] and 11.00 and 10.30 ppm for [PtL]) due to the asymmetric coordination. The 
pyridyl ring protons appear as a multiplet at δ = 8.43-8.10 ppm for [PdL] and δ = 8.56-
8.10 ppm for [PtL] and the rest of the proton signals appear at nearly identical positions 
if they are compared with the corresponding ligand signals. 
13
C NMR spectrum of the free ligand shows carbon signals supporting the 
1
H 
NMR assignments however due to the low solubility of the complexes it was not 
possible to get 
13
C NMR spectra of reasonably quality. 
The electronic absorption spectra of both [H2L] ligand and [PdL] and [PtL] 
complexes exhibit two  intense band in the region 250-400 nm, which can ascribed to 
ligand-centered n→* and →* transitions. In addition the spectra of metal 
complexes exhibit other less energetic bands assigned to a ligand to metal (LMCT) and 
metal to ligand charge transfer (MLCT) transitions [27]. 
3.2. Description of the crystal structures 
[PdL]·DMSO and [PtL]·DMSO were isolated as neutral compounds. The most 
significant crystallographic data for these complexes are shown in Table 1, whereas 
selected bond lengths and bond angles are presented in Table 2.  
 
Insert Table 1 
 
The structures together with the atom labeling schemes are shown in Figures 1 
and 2. Both compounds are isostructural hence displaying nearly identical cell 
parameters, crystallize in the triclinic Pī space group with Z=2 and the asymmetric units 
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contain one molecule of the neutral complex and one dimethyl sulfoxide solvent 
molecule. 
 
Insert Figure 1 
 
Insert Figure 2 
 
The metal ion presents a square planar geometry where the 
bis(thiosemicarbazonate) ligand is coordinated to the metal ion through the pyridine 
nitrogen atom and the azomethine nitrogen and thione sulfur atoms from one 
thiosemicarbazone arm and being the fourth coordination position occupied by the  
hydrazine nitrogen atom of the other thiosemicarbazone arm generating two typical five 
membered (PdSCNN and PdNCCN or PtSCNN and PtNCCN) and one six membered 
(PdNNCCN or PtNNCCN) chelate rings.  Coordination by hydrazine nitrogen atom 
instead of the azomethine nitrogen atom, although uncommon, has been found in the 
bibliography for some d
8
 bis(thiosemicarbazone) complexes [23, 28-31]. 
The M–N and M–S bond distances are similar to those found in other 
palladium(II) and platinum(II) complexes. It is important to note that the two 
thiosemicarbazone moieties, which are symmetrically deprotonated, coordinate in a 
different fashion. Upon coordination the bidentate-N,S arm undergoes significant 
evolution from the thione to the thiol form which is reflected in C–S distance of 
1.779(4) for [PdL]·DMSO and 1.804(10) for [PtL]·DMSO while the monodentate-
thiosemicarbazone [N(3), hydrazine nitrogen atom] arm maintains its thione form as 
reflects in their C–S bond length of 1.673(5) for [PdL]·DMSO and 1.672(3) Å for 
[PtL]·DMSO, typical of double C=S bond.  
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Insert Table 2 
 
Comparison of C–N and N–N bond distances with typical lengths of single and 
double bonds [C-N 1.47, C=N 1.28, N-N 1.45, N=N 1.25  ] suggests extensive charge 
delocalization over the thiosemicarbazone moieties [32, 33] and also agree with the 
thiolate tautomeric form of the bidentate thiosemicarbazonate arm and the thione 
tautomeric form of the monodentate one (Scheme 2). 
 
Insert Scheme 2 
 
 
Inspection of the angles formed between the metal ion (M=Pd
2+
, Pt
2+
) and the 
coordinated atoms shows that the metal is contained within a slightly distorted square-
planar environment being the bond angles between adjacent coordinating atoms in the 
80.5-104.2º range. 
The crystal structures are stabilized by intermolecular hydrogen interactions 
involving the N(7) atom of the bidentate thiosemicarbazonate arms and the oxygen 
atom of DMSO solvent molecule being the N(7)-H(7)···O(1) contact distance 2.83 Å for 
both complexes and <(NHO) angle 170.4º for [PdL] and 169,2º for [PtL]. Further 
stabilization of the crystal packing is provided by intermolecular - stacking 
interactions involving the whole planar bis(thiosemicarbazone)-metal skeleton (Figure 
3), with an interplane separation about  3.5 Å. 
Insert Figure 3 
3.3. In vitro antiproliferative activity  
To assess the antitumor potential of the synthesized compounds, its 
antiproliferative activity (in powder solid form) was tested in vitro against a panel of 
human cancer cells lines containing examples of lung (NCI-H460), breast (T-47D) and 
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ovarian (A2780 and A2780cisR) cancers. For comparison purposes, the cytotoxicity of 
cisplatin was always evaluated under the same experimental conditions.  
Table 3 shows that both the p-chlorophenyl substituted free ligand H2L and its 
platinum(II) complex [PtL] present important antiproliferative activity in the low-
micromolar range, against ovarian (A2780, cisplatin sensitive, and A2780cisR, cisplatin 
resistant) and breast (T-47D) cancer cells. It is remarkable to note that both compounds 
exhibit better cytotoxic effects against T-47D cells than cisplatin by comparing their 
IC50 values. 
The A2780cisR cell line encompasses all of the known major mechanisms of 
resistance to cisplatin: reduced drug transport, enhanced DNA repair/tolerance, and 
elevated GSH levels. The ability of H2L and [PtL] compounds to circumvent cisplatin-
acquired resistance was confirmed from the resistance factor values, RF (defined as IC50 
in A2780cisR/IC50 in A2780) since both have a much better RF value than cisplatin. An 
RF value of < 2 was considered to denote non-cross-resistance and therefore these 
compounds are able to circumvent cisplatin resistance [34,35]. 
 From a chemical point of view, analysis of these data together with those of our 
previous study [23] in which the related ligand 2,6-diacetylpyridine bis(
4
N-p-
tolylthiosemicarbazone), H2L
2
, resulted inactive in both A2780 and A2780cisR cell 
lines and its [PtL
2
] complex showed a slightly lower antiproliferative activity than [PtL] 
complex (see table 3) suggests that the presence of one electron withdrawing group 
attached to the 
4
N atom of the thiosemicarbazone moiety results beneficial for the 
antiproliferative activity of the bis(thiosemicarbazone) ligands of the 2,6-
diacetylpyridine series.  
 
Insert Table 3 
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3.4. DNA Interaction Studies  
In order to initially address if any direct interaction with DNA is part of the 
mechanism of action of the compounds, UV-visible absorption spectra in absence and 
presence of CT-DNA were carried out for H2L ligand, which have a significant effect 
against the tested cell lines. 
Absorption spectral studies 
The binding affinity between DNA and H2L ligand can be detected by UV-Vis 
absorption spectroscopy by measuring the changes in the absorption properties of: a) 
DNA (for a variable H2L concentration) or b) H2L
 
ligand molecule (for a variable DNA 
concentration). 
The UV-Vis absorption spectrum of the typical β-form DNA exhibits a 
characteristic →* band at 260 nm as consequence of the chromophoric groups in 
purine and pyrimidine moieties. Compounds binding with DNA through intercalation 
are consistent with hypochromism (decrease in DNA band absorption), resulted of a 
stacking interaction between the aromatic ligand chromophore and the base pair of 
DNA. In case of compounds binding with DNA through external contact (including 
groove binding and electrostatic attraction) usually hyperchromism (increase in DNA 
band absorption) is observed which is attributable of a contraction and overall damage 
of the secondary structure of DNA [36]. 
Thus, the absorption spectrum of CT-DNA in presence of H2L was recorded, by 
keeping constant CT-DNA concentration (1.7x10
-4
 M) in diverse [CT-DNA]/[H2L] 
mixing ratios (R = 0.5-1.5) and monitoring the change in the absorption intensity of the 
typical CT-DNA spectral band at 260 nm. As Figure 4 shows, when the concentration 
of H2L
 
is gradually increased a significant increase in absorption of the DNA band 
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occurs being the percentage of hyperchromism observed [% hyperchromism = (ADNA 
bound – ADNA free) / ADNA bound] about 40 %. 
 
Insert Figure 4 
 
 
 These characteristics suggest non-covalent surface (major or minor groove) 
binding along outside of DNA helix. The above observations are comparable to those 
reported earlier for various neutral bis(thiosemicarbazone) palladium and platinum 
complexes [37, 38]. 
The H2L
 
ligand exhibit, in DMSO:Tris buffer (2.5:100) mixture, one broad 
intense band of intraligand π-π* transition at 250 nm and other less intense of 
intraligand n-π* transition at 337 nm and any interaction with DNA could perturb it. 
 Thus, in order to determine the intrinsic binding constant (Kb), absorption 
titration experiments were performed by maintaining a constant H2L concentration (50 
µM) while gradually increasing the concentration of DNA (0 - 40 µM) and monitoring 
the change in the absorption intensity of the intraligand charge transfer band. While 
measuring the absorption spectra, an equal amount of DNA was added to both the test 
solution and the reference solution to eliminate the absorbance of DNA itself. The data 
were then fitted to the following equation, that is only valid for low compound:DNA 
ratios (i.e., far from the DNA saturation) and assumes no binding cooperativity [39]: 
 
[DNA] / (a-f) = [DNA] / (b-f) + 1 / {Kb (b-f)} 
where [DNA] is the concentration of the nucleic acid in base pairs, a is the apparent 
absorption coefficient obtained by calculating Aobs/[compound], and f and b are the 
absorption coefficients of the free and the fully bound compound, respectively.  
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A plot (Figure 5) of [DNA]/(εb- εf) versus [DNA], gives a slope of 1/(εb- εf) and a Y-
intercept equal to 1/{Kb(εb-εf)}. The intrinsic binding constant Kb is calculated as the 
ratio of the slope to the Y-intercept.  
 
Insert Figure 5 
 
  On titration of CT-DNA a slight increase in the absorptivity of this band is 
observed which is indicative of interaction between the electronic states of the ligand 
chromophore with that of DNA bases. The magnitude of intrinsic binding constant was 
calculated to be 7.03x10
4 
M
−1
 (correlation coefficient R
2 
= 0.99) which is modest, 
however it should be kept in mind that the biological activity of α-(N)-heterocyclic 
thiosemicarbazones is not only due to their non- covalent DNA binding but they are 
also potent inhibitors of DNA synthesis and repair through RR inactivation. This fact 
could explain the good cytotoxic activity that both free ligand and platinum complex 
have demonstrated. Further studies and more practical experiments are required to 
elucidate the biochemical mechanisms involved in their activity. 
4. Conclusions 
A new family of Pt(II) and Pd(II) bis(thiosemicarbazone) compounds of the 2,6-
diacetylpyridine series containing an aryl ring with an electron withdrawing substituent 
(p-chlorophenyl group) has been successfully prepared and characterized. 
This study has identified both the free ligand H2L and the Pt(II) complex [PtL] 
as having high antiproliferative activity since they are capable of not only circumvent 
cisplatin resistance in A2780cisR cells but they also exhibit high antiproliferative 
activity against breast (T-47D) cancer cells.  
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CAPTIONS 
 
Scheme 1. Structure of 2,6-diacetylpyridine bis(
4
N-p-chlorophenylthiosemicarbazone), 
H2L ligand. 
Scheme 2. Delocalization System in the Thiosemicarbazonate moiety 
 
Figure. 1. Molecular structure of [PdL]. The displacement ellipsoids are drawn at the 
50% probability. 
Figure. 2. Molecular structure of [PtL]. The displacement ellipsoids are drawn at the 
50% probability. 
Figure. 3. Crystal packing view of [PdL]·DMSO along a axis, dashed lines denote π···π 
interactions. 
Figure. 4. UV absorption spectrum of CT-DNA in the absence (black curve) and 
presence of increasing amounts of compound H2L. The data were collected for [CT-
DNA] = 1.7x10
−4
 M and [H2L] = 0, 2.5x10
-6
, 6.0x10
-5
, 8.0x10
-5
, 1.25x10
-4
 M (the arrow 
shows the changes upon increasing amounts of complex). 
Figure. 5. UV absorption spectrum of H2L in the absence (black curve) and presence of 
increasing amounts of compound CT-DNA. The data were collected for [H2L] = 5x10
−5
 
M and [CT-DNA] = 0, 20x10
-6
, 60x10
-6
, 70x10
-6
, 75x10
-6
 M. The insert shows a fitting 
of the absorbance data used to obtain the binding constants. 
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Abstract 
Preparation and characterization of 2,6-diacetylpyridine bis(
4
N-para-
chlorophenylthiosemicarbazone) ligand, H2L, and its palladium(II) and platinum(II) 
complexes [PdL] and [PtL], is described. The crystal and molecular structure of the two 
new complexes has been determined by single crystal X-ray diffraction. The ligand act 
as dianionic tetradentate donor coordinating to the metal center in a square planar 
geometry through the pyridine nitrogen Npyridinic atom and the azomethine nitrogen 
Niminic and thione sulfur the S atoms from one thiosemicarbazone arm, the fourth 
coordination position is occupied by the hydrazine nitrogen atom Nhydrazinic of the other 
arm. New free ligand and its metal complexes have been evaluated for antiproliferative 
activity in vitro against NCI-H460, T-47D, A2780 and A2780cisR human cancer cell 
lines. The cytotoxicity data suggest that these compounds may be endowed with 
important antitumor properties, especially H2L and [PtL] since they are capable of not 
only circumvent cisplatin resistance in A2780cisR cells but also exhibit high 
antiproliferative activity in breast cancer T-47D cells. The interaction of H2L with calf 
thymus DNA was also investigated and its binding constant (Kb) determined. 
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1. Introduction 
Platinum metallo-drugs are among the most effective agents for the treatment of cancer 
however its clinical utility is restricted due to the frequent development of drug 
resistance, the limited spectrum of tumors against which these drugs are active and also 
the severe normal tissue toxicity [1-5]. These disadvantages have driven the 
development of improved platinum-based anticancer drugs whose structure and mode of 
action differ from that of cisplatin, especially those that interact with specific molecular 
targets as for example are the processes associated to DNA: transcription, replication 
and repair [6-9].  
In this regard, of particular interest are compounds targeting ribonucleotide 
reductase (RR), enzyme that catalyzes the reduction of ribonucleotides to 
deoxyribonucleotides and provides the building blocks for the de novo DNA synthesis 
in all living cells. Cancer cells require increased RR activity to meet the demand for 
deoxyribonucleotides that are needed to support their rapid proliferation. Thus 
inhibition of RR activity leads to inhibition of DNA synthesis and repair, and also 
induces cell cycle arrest and apoptosis [10-12].  
α-(N)-heterocyclic thiosemicarbazones, (N)-TSCs, have been reported to be 
among the most effective RR inhibitors yet identified and many efforts have been 
devoted to the study of the structure–activity relationship of thiosemicarbazone 
derivatives. The anticancer activity of (N)-TSCs is closely related to the nature of the 
heterocyclic ring of the parent aldehyde or ketone, metal chelation ability and terminal 
amino substitution [13-20]. In this sense pyridine ring itself is a part of many natural 
and synthetically prepared pharmaceuticals and moreover it plays a significant role in 
many biological processes like nicotinamide adenine dinucleotide phosphate NADP or 
the important vitamins niacin and pyridoxine (vitamins B3 and B6) [21, 22].  
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Keeping in view the above observations and as part of our systematic 
investigation on the coordination chemistry of thiosemicarbazone derivatives we 
recently reported palladium(II) and platinum(II) complexes derived of 2,6-
diacetylpyridine bis(
4
N- ortho-tolylthiosemicarbazone) and 2,6-diacetylpyridine bis(
4
N-
para-tolylthiosemicarbazone)
 
ligands. The in vitro antitumor studies have shown that 
these complexes exhibit important antiproliferative activity in A2780 and A2780cisR 
human cancer cell lines and these results encouraged us to further investigate their 
cytotoxic properties as well as those of novel derivatives [23].  
This work is aimed to determine if the presence of an aryl ring with an electron 
withdrawing substituent (such as para-chlorophenyl group) results beneficial for the 
antitumor activity of 2,6-diacetylpyridine derived bis(
4
N-subtituted thiosemicarbazones) 
ligands derived from 2,6-diacetylpyridine. Therefore here we describe the synthesis and 
chemical characterization of the new 2,6-diacetylpyridine bis(
4
N-para- 
chlorophenylthiosemicarbazone) ligand, H2L, (Scheme 1) and its palladium(II) and 
platinum(II) complexes, [PdL] and [PtL].  
 
 
Scheme 1. Structure of 2,6-diacetylpyridine bis(
4
N-para-
chlorophenylthiosemicarbazone), H2L ligand 
 
The cytotoxic activity of the new compounds synthesized and cisplatin (assumed 
as the reference antitumor drug) against four human cancer cell lines: NCI-H460 (non-
small cell lung cancer), T-47D (breast cancer), A2780 and A2780cisR (epithelian 
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epithelial ovarian cancer) has been studied. The interaction of H2L with calf thymus 
DNA (CT-DNA) was also investigated and its binding constant (Kb) determined. 
 
2. Experimental 
2.1. Measurements 
Elemental analyses were performed on a LECO CHNS-932 microanalyzer. Fast 
atom bombardment (FAB) mass spectra (MS) were performed on a VG AutoSpec 
spectrometer (mNBA: nitrobenzyl alcohol matrix). 
1
H NMR spectra (DMSO-d6) were 
recorded on Bruker AMX-300 spectrometer. All cited physical measurements were 
obtained out by the Servicio Interdepartamental de Investigación (SIdI) of the 
Universidad Autónoma de Madrid. 
Melting points were determined with a Stuart Scientific SMP3 apparatus. 
Infrared spectra (KBr pellets) were recorded on a Bomen–Michelson spectrophotometer 
(4000–400 cm-1). 13C NMR spectra were recorded on a 400 Advance Bruker Fourier 
Transform spectrometer. Electronic spectra were recorded on a Thermo Scientific 
Evolution 260 Bio UV-visible (UV-VIS) spectrophotometer.  
2.2. Materials 
Solvents were purified and dried according to standard procedures. Hydrazine 
hydrate, 2,6-diacetylpyridine, para-chlorophenyl isothiocyanate, PdCl2(PPh3)2 and 
PtCl2(PPh3)2 were commercially available.    
2.3. Synthesis of compounds 
2,6-Diacetylpyridine bis(
4
N-para-chlorophenylthiosemicarbazone), H2L. An 
ethanolic solution of hydrazine hydrate (0.250 g, 5 mmol) was added dropwise with 
constant stirring to an ethanolic solution of para-chlorophenyl isothiocyanate (0.848 g, 
5 mmol). The reaction mixture was stirred for one more hour and then the white product 
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para-chlorophenylthiosemicarbazide formed was filtered, washed with cold ethanol and 
diethyl ether, dried in vacuo and recrystallized from ethanol. An ethanolic solution of 
the para-chlorophenylthiosemicarbazide (0.402 g, 2 mmol) was then stirred with 2,6-
diacetylpyridine (0.163 g, 1 mmol) for 5 h. The resulting solution was reduced to half 
volume and the pale yellow solid formed was filtered, washed with ethanol, diethyl 
ether and finally dried in vacuo. 
Yield (80%), mp 220 ºC (decomposes). Elemental analysis found, C, 52.20; H, 4.25; N, 
18.00; S, 12.20; C23H21N7S2Cl2 requires C, 52.107; H, 4.003.99, N, 18.5048; S, 12.109 
%. MS (FAB
+
 with mNBA: nitrobenzyl alcohol matrix) m/z 530.0 for [H2L+H]
+
. IR 
(KBr pellet): υn/cm-1 3335, 3306, 3210 (w, NH); 1588 (s, CN); 827, 809 (w, CS-
thioamide IV); 585 (pyridine ring). 
1
H NMR (300 MHz, d
6
-DMSO, ppm), δ=10.80 [s, 
2
NH, 2H]; 10.20 [s, 
4
NH, 2H]; 8.55 [d, J=7.9 Hz, CH-pyridine, 2H]; 7.85 [t, J=7.9 Hz, 
CH-pyridine, 1H]; 7.60 (d, J=8.7 Hz, aromatic-thiosemicarbazide, 4H); 7.45 (d, J=8.7 
Hz, aromatic-thiosemicarbazide, 4H); 2.50 (s, CH3-diacetylpyridine, 6H). 
13
C NMR (d
6
-
DMSO, ppm), δ=178.3 (C=S); 153.78 (C2,C6-pyridine); 149.85 (C=1N); 138.54 (C4-
pyridine); 137.17 (C3,C5-pyridine); 130.08 (aromatic-thiosemicarbazide); 128.49 
(aromatic-thiosemicarbazide); 128.34 (aromatic-thiosemicarbazide); 127.37 (aromatic-
thiosemicarbazide); 121.96 (aromatic-thiosemicarbazide); 12.98 (CH3-diacetylpyridine). 
UV/VIS (DMSO): λ/nm 250, 337. 
2,6-Diacetylpyridine bis(
4
N-para-chlorophenylthiosemicarbazonato)palladium(II), 
[PdL]. The reaction of H2L ligand with PdCl2(PPh3)2, in toluene, in presence of Et3N, in 
1:1 molar ratios over 20 h at room temperature led to the formation of an orange 
solution which was filtered and left to stand at ambient temperature for two days. The 
brown solid formed was filtered, washed several times with hot water, diethyl ether and 
finally dried in vacuo. 
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Yield (55%), mp >250 ºC. Elemental analysis found, C, 43.35; H, 3.35, N, 15.10; S, 
10.05; C23H19N7S2Cl2Pd requires C, 43.501; H, 3.002, N, 15.404; S, 10.10 %. MS 
(FAB
+
 with mNBA matrix) m/z 636 for [PdL
1
+H]
+
. IR (KBr pellet): υn/cm-1 3243 (s, 
NH); 1595 (s, CN); 830, 804 (vw) (CS-thioamide IV); 603 (pyridine ring). 
1
H NMR 
(300 MHz, d
6
-DMSO, ppm), δ=10.75, 10.18 [s, 4NH, 2H]; 8.43-8.10 [m, CH-pyridine, 
3H]; 7.71-7.34 (m, aromatic-thiosemicarbazide, 8H); 2.72, 2.62 (s, CH3-
diacetylpyridine, 6H). UV/VIS (DMSO): λ/nm 267, 340, 410, 470. 
Recrystallization from DMSO led to the isolation of orange crystals of [PdL]·DMSO 
that were suitable for X-ray-diffraction. 
2,6-Diacetylpyridine bis(
4
N-para-chlorophenylthiosemicarbazonato)platinum(II), 
[PtL]. It was prepared by the same procedure as described for [PdL] by reaction of H2L 
with PtCl2(PPh3)2 and afforded a brown solid. 
 Yield (35%), mp 192 ºC (decomposes). Elemental analysis found, C, 37.90; H, 2.55, N, 
13.60; S, 8.60; C23H19N7S2Cl2Pt requires C, 38.2018; H, 2.605, N, 13.55; S, 8.856 %. 
MS (FAB
+
 with mNBA matrix) m/z 724 for [PtL+H]
+
. IR (KBr pellet): υ/cm-1 3288, 
3208 (s, NH); 1590 (s, CN); 826, 809 (vw) (CS-thioamide IV); 591 (pyridine ring). 
1
H 
NMR (300 MHz, d
6
-DMSO, ppm), δ=11.00, 10.30 [s, 4NH, 2H]; δ=8.56-8.10 [m, CH-
pyridine, 3H]; δ=7.76-7.70 (m, aromatic-thiosemicarbazide, 8H); δ=2.78, 2.71 (s, CH3-
diacetylpyridine, 6H). UV/VIS (DMSO): λ/nm 249, 267, 366. 
Recrystallization from DMSO led to the isolation of orange crystals of [PtL]·DMSO 
that were suitable for X-ray-diffraction. 
2.4. Crystallography 
Data were collected on a Bruker X8 APEX II CCD.  Crystallographic data and 
selected interatomic distances and angles are listed in Table 1. For all compounds, the 
software package SHELXTL was used for space group determination, structure 
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solution, and refinement [24]. The structures were solved by direct methods, completed 
with difference Fourier syntheses, and refined with anisotropic displacement 
parameters. 
CCDC 981268 and 981269 contain the supplementary crystallographic data for 
compounds [PdL] and [PtL] respectively. These data can be obtained free of charge at 
www.ccdc.cam.ac.uk/conts/retrieving.html [or from the Cambridge Crystallographic 
Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44-1223/336-033; e-
mail: deposit@ccdc.cam.ac.uk]. 
2.5. In vitro antiproliferative activity 
The human cancer cells: A2780 and A2780cisR (epithelial ovarian cancer), T-
47D (breast cancer) and NCI-H460  (non-small cell lung cancer); were grown in RPMI-
1640 medium supplemented with 10% foetal bovine serum (FBS) and 2 mM L-
glutamine in an atmosphere of 5% CO2 at 37 °C.  
Cell proliferation was evaluated by the sulforhodamine B assay. Cells were 
plated in 96-well sterile plates at a density of 1.5·10
4
 (for NCI-H460), 4·10
3
 (for A2780 
and A2780cisR) or 5·10
3
 (for T-47D) cells per well with 100μL of medium and were 
then incubated for 24 h (A2780, A2780cisR and NCI-H460) or 48 h (T-47D). After 
attachment to the culture surface the cells were incubated with various concentrations of 
the compounds tested freshly dissolved in DMSO (1 mg/mL) and diluted in the culture 
medium (DMSO final concentration 1%) for 48 h (for NCI-H460) or 96 h (for A2780, 
A2780cisR and T-47D). The cells were fixed by adding 50 μL of 30% trichloroacetic 
acid (TCA) per well.  
The plates were incubated at 4 °C for 1 h and then washed five times with 
distilled water. The cellular material fixed with TCA was stained with 0.4% 
sulforhodamine B dissolved in 1% acetic acid for 10 min. Unbound dye was removed 
9 
 
by rinsing with 0.1% acetic acid. The protein-bound dye was extracted with 10 mM 
unbuffered Tris base for determination of optical density (at 515 nm) in a Tecan Ultra 
Evolution spectrophotometer. 
The effects of compounds were expressed as corrected percentage inhibition 
values according to the following equation: 
 
% inhibition = [1−(T/C)] × 100 
where T is the mean absorbance of the treated cells and C the mean absorbance in the 
controls. 
The inhibitory potential of compounds was measured by calculating 
concentration–percentage inhibition curves, these curves were adjusted to the following 
equation: 
E = Emax / [1+(IC50/C)
n
] 
where E is the percentage inhibition observed, Emax is the maximal effects, IC50 is the 
concentration that inhibits 50% of maximal growth, C is the concentration of 
compounds tested and n is the slope of the semi-logarithmic dose–response sigmoid 
curves. This non-linear fitting was performed using GraphPad Prism software [25].  
For comparison purposes, the antiproliferative activity of cisplatin was evaluated 
under the same experimental conditions. All compounds were tested in two independent 
studies with triplicate points. These experiments were carried out at the Unidad de 
Evaluación de Actividades Farmacológicas de Compuestos Químicos (USEF), 
Universidad de Santiago de Compostela. 
2.6. DNA-Binding Experiments 
  CT-DNA stock solution was prepared by dissolving the lyophilized sodium salt 
in Tris-buffer (NaCl 50 mM, Tris-HCl 5 mM, pH was adjusted to 7.2 with NaOH 0.5 
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M) by stirring for 5 hours. The CT-DNA solution was standardized 
spectrophotometrically [26] by using its known molar absorption coefficient at 260 nm 
(6600 M
-1
·cm
-1
). The ratio of UV absorbance at 260 and 280 nm, A260/A280, of ca. 1.9, 
indicating that the DNA was sufficiently free of protein. Stock solution was kept frozen 
until the day of the experiment. 
 Concentrated stock solutions (5·10
-3
 M and 5·10
-5
) of H2L were prepared 
dissolving the compound in DMSO. From these stock solutions, for all experiments the 
desired concentration of compound was achieved by dilution with Tris-buffer (NaCl 50 
mM, Tris-HCl 5 mM, pH was adjusted to 7.2 with NaOH 0.5 M) to give homogeneous 
solutions with DMSO content of less than 2.5 %. 
  To investigate the binding mode, spectrophotometric titrations were performed 
at a ﬁxed DNA concentration equal to 1.7·10-4 M with increasing concentration of H2L 
(0-125 M) compounds (R=[CT-DNA]/[compound]) and monitoring the absorbance 
change at the wavelength maximum 260 nm after incubation (10 min. at 37ºC). 
  To calculate the binding parameters, the spectrophotometric titrations were 
performed with increasing concentration of DNA (0-40 M) at a ﬁxed compound 
concentration equal to 50
 M (r=[compound]/[DNA]) and monitoring the absorbance 
change in one  characteristic charge transference band of the compound after incubation 
(10 min. at 37ºC). 
 
3. Results and discussion 
3.1.  Synthesis and spectroscopic characterization 
  A new 2,6-diacetylpyridine bis(
4
N-monosubstituted thiosemicarbazone) ligand 
has been synthesized with high purities and acceptable yields. The yellow compound 
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obtained is stable to air and moisture and was characterized by elemental analysis, 
FAB
+
 spectrometry and IR and 
1
H NMR (
1
H and 
13
C) spectroscopy.  
Reaction of 2,6-diacetylpyridine bis(
4
N-para-chlorophenylthiosemicarbazone) 
ligand with equimolar amount of  MCl2(PPh3)2, where M = Pd(II) or Pt(II), led to the 
isolation of neutral mononuclear complexes [PdL] and [PtL] in which the 
bis(thiosemicarbazone) behaves as dianionic ligand with deprotonation of hydrazinic 
hydrazine (
2
NH) protons and [NNNS] donor set.  
Both complexes were characterized by routine analytical and spectroscopic 
techniques. Analytical data are consistent with the formulation given, thus in the FAB
+
 
mass spectra exhibited a very weak ion the molecular ion is seen as a small peak at m/z 
= 636 for [PdL] and m/z = 724 for [PtL] which corresponded to the predicted molecular 
weight of the [M+H]
+
 ions and moreover the isotopic patterns of this signal fit well with 
the theoretical isotopic distributions. 
The significant IR vibrational bands and the 
1
H chemical shift values of the free 
ligand and its complexes are listed in the Experimental section and Scheme 1 shows the 
numbered structure of the free ligand. As the X-ray study has shown, during metal 
complexation, the ligand behaves as a tetradentate dianionic forming two five-
membered and one six-membered chelate rings around the metal center. The high 
delocalization and the asymmetric coordination hinder the IR analysis. The stretching 
vibration υ(C=N) and the in-plane pyridine deformation bands are slightly shifted to 
higher wavenumbers which are consistent with the implication of iminic imine and 
pyridinic pyridine nitrogen atoms in the coordination however this induces only minor 
changes in υ(C=S) thioamide IV band which decreases slightly in intensity. 
In the 
1
H NMR spectrum of the double-armed H2L ligand, two independent 
singlets at δ = 10.80 and 10.20 ppm are observed for 2N-hydrazinic and 4N-amidic 
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hydrogens >C=N-
2
NH- and –C(S)-4NH- protons respectively. A doublet at δ = 8.55 
ppm and a triplet at δ = 7.85 ppm are assigned to pyridyl ring protons. Aromatic para-
chlorophenyl protons appear as a multiplet at δ = 7.60-7.45 ppm and a sharp singlet at δ 
= 2.50 is assigned to the methyl protons.  In [PdL] and [PtL] complexes, the anionic 
coordination of the ligand is evidenced by the disappearance of the signal corresponding 
to 
2
N-hydrazinic hydrogens the >C=N-
2
NH- protons. On the other hand, 
4
N-amidic 
hydrogens the –C(S)-4NH- protons appear two independent signals (10.75 and 10.218 
ppm for [PdL] and 11.00 and 10.30 ppm for [PtL]) due to the asymmetric coordination. 
The pyridyl ring protons appear as a multiplet at δ = 8.43-8.10 ppm for [PdL] and δ = 
8.56-8.10 ppm for [PtL] and the rest of the proton signals appear at nearly identical 
positions if they are compared with the corresponding ligand signals. 
13
C NMR spectrum of the free ligand shows carbon signals supporting the 
1
H 
NMR assignments however due to the low solubility of the complexes it was not 
possible to get 
13
C NMR spectra of reasonably quality. 
The electronic absorption spectra of both [H2L] ligand and [PdL] and [PtL] 
complexes exhibit two  intense band in the region 250-400 nm, which can ascribed to 
ligand-centered n→* and →* transitions. In addition the spectra of metal 
complexes exhibit other less energetic bands assigned to a ligand to metal (LMCT) and 
metal to ligand charge transfer (MLCT) transitions [27]. 
3.2. Description of the crystal structures 
[PdL]·DMSO and [PtL]·DMSO were isolated as neutral compounds. The most 
significant parameters crystallographic data for these complexes are shown in Tables 1, 
whereas selected bond lengths and bond angles are presented in Table and 2.  
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Table 1 Crystal data and structure refinement for [PdL]·DMSO and [PtL]·DMSO 
compounds. 
 [PdL]·DMSO [PtL]·DMSO 
Molecular formula C25H25Cl2N7OPdS3 C25H25Cl2N7OPtS3 
Formula weight 713.00 801.69 
Temperature (K) 100(2) 100(2) 
Wavelength (Å) 0.71073 0.71073 
Crystal system Triclinic Triclinic 
Space group Pī Pī 
a(Å) 7.4630(5) 7.484(3) 
b(Å) 13.2509(7) 13.251(6) 
c(Å) 14.6594(9) 14.680(6) 
α/º 77.351(3) 76.611(14) 
β/º 87.513(3) 87.296(15) 
γ/º 81.522(3) 80.818(15)g 
Volume(Å
3
) 1398.96(15) 1398.0(10) 
Z 2 2 
Density (calculated) (g/cm
3
) 1.693 1.905 
Absorption coefficient (mm-
1
) 1.113 5.469 
F(000) 720 784 
Crystal size (mm3) 0.57 x 0.09 x 0.03 0.40 x 0.04 x 0.02 
Index ranges -8≤h≤8, -15≤k≤15, -17≤l≤17 -8≤h≤8, -15≤k≤15, -16≤l≤17 
Reflections collected 47797 15003 
Independent reflections 5086  4672  
Data / restraints / parameters 5086 /0/356 4672 /0/356 
Goodness-of-fit on F2 1.066 1.002 
Final R indices [I>2σ(I)] R1 = 0.0380, wR2 = 0.1116 R1 = 0.0450, wR2 = 0.1074 
R indices (all data) R1 = 0.0498, wR2 = 0.1297 R1 = 0.0748, wR2 = 0.1409 
Largest diff. peak and hole, e.Å
-3
 1.126 and -0.783 1.606 and -2.739 
 
The structures together with the atom labeling schemes are shown in Fig. 
Figures 1 and 2. Both compounds are isostructural hence displaying nearly identical cell 
parameters, crystallize in the triclinic Pī space group with Z=2 and the asymmetric units 
contain one molecule of the neutral complex and one dimethyl sulfoxide solvent 
molecule. 
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Fig. 1. Molecular structure of [PdL] complex. The displacement ellipsoids are drawn at 
the 50% probability. 
 
Fig. 2. Molecular structure of [PtL] complex. The displacement ellipsoids are drawn at 
the 50% probability. 
The metal ion presents a square planar geometry being where the 
bis(thiosemicarbazonate) ligand attached is coordinated to the metal ion through the 
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Npyridinic pyridine nitrogen atom and the Niminic azomethine nitrogen and the S thione 
sulfur atoms from one thiosemicarbazone arm and being the fourth coordination 
position occupied by the Nhydrazinic hydrazine nitrogen atom of the other 
thiosemicarbazone arm generating two typical five membered (PdSCNN and PdNCCN 
or PtSCNN and PtNCCN) and one six membered (PdNNCCN or PtNNCCN) chelate 
rings.  Coordination by Nhydrazinic hydrazine nitrogen atom instead of Niminic, the 
azomethine nitrogen atom, although uncommon, has been found in the bibliography for 
some d
8
 bis(thiosemicarbazone) complexes [23, 28-31]. 
The M–N and M–S bond distances are similar to those found in other 
palladium(II) and platinum(II) complexes. It is important to note that the two 
thiosemicarbazone moieties, which are symmetrically deprotonated, coordinate in a 
different fashion. Upon coordination the bidentate-N

S,S arm undergoes significant 
evolution from the thione to the thiol form which is reflected in C–S distance of 
1.779(4) for [PdL]·DMSO and 1.804(10) for [PtL]·DMSO while the monodentate-
Nhidrazinic thiosemicarbazone (
3
N, hydrazine nitrogen atom) arm maintains its thione form 
as reflects in their C–S bond length of 1.673(5) for [PdL]·DMSO and 1.672(3) Å for 
[PtL]·DMSO, typical of double C=S bond.  
Table 2. Selected bond distances (Å) and angles (º) for [PdL]·DMSO and 
[PtL]·DMSO. 
[PdL]·DMSO                                                                  [PtL]·DMSO  
Bond lengths (Å)     
S(1)-C(8) 1.673(5)   S(1)-C(17) 1.804(10) 
S(2)-C(17) 1.779(4)   S(2)-C(10) 1.672(11) 
C(6)-N(2) 1.291(6)   C(2)-N(5) 1.299(14) 
C(8)-N(3) 1.389(6)   C(8)-N(2) 1.298(14) 
C(8)-N(4) 1.373(6)   C(10)-N(3) 1.424(14) 
C(9)-N(4) 1.406(6)   C(10)-N(4) 1.347(13) 
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C(15)-N(5) 1.304(6)   C(11)-N(4) 1.421(13) 
C(17)-N(6) 1.297(6)   C(17)-N(6) 1.290(14) 
C(17)-N(7) 1.367(6)   C(17)-N(7) 1.348(14) 
C(18)-N(7) 1.402(6)   C(23)-N(7) 1.411(13) 
Pd(1)-N(1) 2.029(4)   Pt(1)-N(1) 2.017(9) 
Pd(1)-N(3) 2.044(4)   Pt(1)- N(3) 2.032(9) 
Pd(1)-N(5) 1.979(4)   Pt(1)- N(5) 1.985(9) 
Pd(1)-S(2) 2.2842(11)   Pt(1)-S(1) 2.279(3) 
      
Bond angles (º)     
N(1)-Pd(1)-N(3) 91.73(15)   N(1)-Pt(1)-N(3) 91.8(3) 
N(1)-Pd(1)-N(5) 80.58(15)   N(1)-Pt(1)-N(5) 80.5(4) 
N(3)-Pd(1)-S(2) 104.2(11)   N(3)-Pt(1)-S(2) 103.7(2) 
N(5)-Pd(1)-S(2) 83.43(11)   N(5)-Pt(1)-S(2) 83.0(3) 
N(1)-Pd(1)-S(2) 163.95(11)   N(1)-Pt(1)-S(2) 164.5(3) 
N(3)-Pd(1)-N(5) 172.25(15)   N(3)-Pt(1)-N(5) 172.2(4) 
 
Comparison of C–N and N–N bond distances with typical lengths of single and 
double bonds [C-N 1.47, C=N 1.28 Å, N-N 1.45, N=N 1.25   ] suggests extensive 
charge delocalization over the thiosemicarbazone moieties [32, 33] and also agree with 
the thiolate tautomeric form of the bidentate thiosemicarbazonate arm and the thione 
tautomeric form of the monodentate one (Scheme 2). 
 
 
Scheme 2. Delocalization System in the Thiosemicarbazonate moiety 
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Inspection of the angles formed between the metal ion (M=Pd
2+
, Pt
2+
) and the 
coordinated atoms shows that the metal is contained within a slightly distorted square-
planar environment being the bond angles between adjacent coordinating atoms in the 
range 80.5-104.2º range. 
The crystal structures are stabilized by intermolecular hydrogen interactions 
involving the N(7) atom of the bidentate thiosemicarbazonate arms and the oxygen 
atom of DMSO solvent molecule being the N(7)-H(7)···O(1) contact distance 2.83 Å for 
both complexes and <(NHO) angle 170.4º for [PdL] and 169,2º for [PtL]. Further 
stabilization of the crystal packing is provided by intermolecular - stacking 
interactions involving the whole planar bis(thiosemicarbazone)-metal skeleton (Figure 
3), with an interplane separation of about  3.5 Å. 
 
Fig 3. Crystal packing view of [PdL]·DMSO along a axis, dashed lines denote 
π···π interactions. 
 
3.3. In vitro antiproliferative activity  
To assess the antitumor potential of the synthesized compounds, its 
antiproliferative activity (in powder solid form) was tested in vitro against a panel of 
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human cancer cells lines containing examples of lung (NCI-H460), breast (T-47D,) and 
ovarian (A2780 and A2780cisR) cancers. For comparison purposes, the cytotoxicity of 
cisplatin was always evaluated under the same experimental conditions.  
Table 3 shows that both the p-chlorophenyl substituted free ligand H2L and its 
platinum(II) complex [PtL] present important antiproliferative activity in the low-
micromolar range, against ovarian (A2780, cisplatin sensitive, and A2780cisR, cisplatin 
resistant) and breast (T-47D) cancer cells. It is remarkable to note that both compounds 
exhibit better cytotoxic effects against T-47D cells than cisplatin by comparing their 
IC50 values. 
The A2780cisR cell line encompasses all of the known major mechanisms of 
resistance to cisplatin: reduced drug transport, enhanced DNA repair/tolerance, and 
elevated GSH levels. The ability of H2L and [PtL] compounds to circumvent cisplatin-
acquired resistance was confirmed from the resistance factor values, RF (defined as IC50 
in A2780cisR/IC50 in A2780) since both have a much better RF than cisplatin. An RF 
value of < 2 was considered to denote non-cross-resistance and therefore these 
compounds are able to circumvent cisplatin resistance [34,35]. 
 From a chemical point of view, analysis of these data together with those of our 
previous study [23] in which the related ligand 2,6-diacetylpyridine bis(
4
N-para-
tolylthiosemicarbazone), H2L
2
, resulted inactive in both A2780 and A2780cisR cell 
lines and its [PtL
2
] complex showed a slightly lower antiproliferative activity than [PtL] 
complex (see table 3) [23] suggests that the presence of one electron withdrawing group 
attached to the 
4
N atom of the thiosemicarbazone moiety results beneficial for the 
antiproliferative activity of the bis(thiosemicarbazone) ligands of the 2,6-
diacetylpyridine series.  
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Table 3. In vitro antiproliferative activity of bis(thiosemicarbazone) compounds H2L, 
[PdL] and [PtL] complexes and H2L
2
, [PtL
2
] and cisplatin, evaluated in human T-47D 
(breast cancer), A2780 and A2780cisR (epithelian ovarian cancer) cell lines.  
The IC50 values are averages of two independent determinations. 
ND = not determined 
a
 Values taken from Ref. [23] 
 
3.4. DNA Interaction Studies  
In order to initially address if any direct interaction with DNA is part of the 
mechanism of action of the compounds, UV-visible absorption spectra in absence and 
presence of calf thymus DNA (CT-DNA) were carried out for H2L ligand, which have a 
significant effect against the tested cell lines. 
Absorption spectral studies 
The binding affinity between DNA and H2L ligand can be detected by UV-Vis 
absorption spectroscopy by measuring the changes in the absorption properties of: a) 
  IC50±SD (µM)   
 
A2780 A2780cisR T-47D             RF  
IC50(A2780cisR)/IC50(A2780) 
        H2L
 7.16±0.14 13±1 7.42±0.14 1.8 
[PdL] 24±1 >100 >100 > 4.2 
[PtL] 7.12±0.21 9.13±0.07 9.17±0.07 1.3 
        H2L
2 >100
a 
>100
a ND --- 
[PtL
2
] 20±2
a 
18±1
a ND 1.1 
Cisplatin 0.88±0.01 7.77±0.10 12±1 8.8 
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DNA (for a variable H2L concentration) or b) H2L
 
ligand molecule (for a variable DNA 
concentration). 
The UV-Vis absorption spectrum of the typical Bβ-form DNA exhibits a 
characteristic →* band at 260 nm as consequence of the chromophoric groups in 
purine and pyrimidine moieties. Compounds binding with DNA through intercalation 
are consistent with hypochromism (decrease in DNA band absorption), resulted of a 
stacking interaction between the aromatic ligand chromophore and the base pair of 
DNA. In case of compounds binding with DNA through external contact (including 
groove binding and electrostatic attraction) usually hyperchromism (increase in DNA 
band absorption) is observed which is attributable of a contraction and overall damage 
of the secondary structure of DNA [36]. 
Thus, the absorption spectrum of CT-DNA in presence of H2L was recorded, by 
keeping constant CT-DNA concentration (1.7·10
-4
 M) in diverse [CT-DNA]/[H2L] 
mixing ratios (R = 0.5-1.5) and monitoring the change in the absorption intensity of the 
typical CT-DNA spectral band at 260 nm. As Figure 4 shows, when the concentration 
of H2L
 
is gradually increased a significant increase in absorption of the DNA band 
occurs being the percentage of hyperchromism observed [% hyperchromism = (ADNA 
bound – ADNA free) / ADNA bound] about 40 %. 
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Fig. 4. UV absorption spectrum of CT-DNA in the absence (black curve) and presence of 
increasing amounts of compound H2L. The data were collected for [CT-DNA] = 1.7·10
−4
 M 
and [H2L] = 0, 2.5·10
-6
, 6.0·10
-5
, 8.0·10
-5
, 1.25·10
-4
 M [CT-DNA]/[H2L] mixing ratios R = 
0.5–1.5 (the arrow shows the changes upon increasing amounts of complex). 
 
 These characteristics suggest non-covalent surface (major or minor groove) 
binding along outside of DNA helix. The above observations are comparable to those 
reported earlier for various neutral bis(thiosemicarbazone) palladium and platinum 
complexes [37, 38]. 
The H2L
 
ligand exhibit, in DMSO:Tris buffer (2.5:100) mixture, one broad 
intense band of intraligand π-π* transition at 250 nm and other less intense of 
intraligand n-π* transition at 337 nm and any interaction with DNA could perturb it. 
 So Thus, in order to determine the intrinsic binding constant (Kb), absorption 
titration experiments were performed by maintaining a constant H2L concentration (50 
µM) while gradually increasing the concentration of DNA (0 - 40 µM) and monitoring 
the change in the absorption intensity of the intraligand charge transfer band. While 
measuring the absorption spectra, an equal amount of DNA was added to both the test 
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solution and the reference solution to eliminate the absorbance of DNA itself. The data 
were then fitted to the following equation, that is only valid for low compound:DNA 
ratios (i.e., far from the DNA saturation) and assumes no binding cooperativity [39]: 
 
[DNA] / (a-f) = [DNA] / (b-f) + 1 / {Kb (b-f)} 
where [DNA] is the concentration of the nucleic acid in base pairs, a is the apparent 
absorption coefficient obtained by calculating Aobs/[compound], and f and b are the 
absorption coefficients of the free and the fully bound compound, respectively.  
A plot (Figure 5) of [DNA]/(εb- εf) versus [DNA], gives a slope of 1/(εb- εf) and a Y-
intercept equal to 1/{Kb(εb-εf)}. The intrinsic binding constant Kb is calculated as the 
ratio of the slope to the Y-intercept.  
 
Fig. 5. UV absorption spectrum of H2L in the absence (black curve) and presence of 
increasing amounts of compound CT-DNA. The data were collected for [H2L] = 5·10
−5
 M and 
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[CT-DNA] = 0, 20·10
-6
, 60·10
-6
, 70·10
-6
, 75·10
-6
 M [H2L]/[CT-DNA] mixing ratios r = 0.4-
0.7. The insert shows a fitting of the absorbance data used to obtain the binding constants. 
 
  On titration of CT-DNA a slight increase in the absorptivity of this band is 
observed which is indicative of interaction between the electronic states of the ligand 
chromophore with that of DNA bases. The magnitude of intrinsic binding constant was 
calculated to be 7.03·10
2 
M
−1
 (correlation coefficient R
2 
= 0.99) which is modest, 
however it should be kept in mind that the biological activity of α-(N)-heterocyclic 
thiosemicarbazones is not only due to their non- covalent DNA binding but they are 
also potent inhibitors of DNA synthesis and repair through RR inactivation. This fact 
could explain the good cytotoxic activity that both free ligand and platinum complex 
have demonstrated. Further studies and more practical experiments are required to 
elucidate the biochemical mechanisms involved in their activity. 
 
4. Conclusions 
A new family of Pt(II) and Pd(II) bis(thiosemicarbazone) compounds of the 2,6-
diacetylpyridine series containing an aryl ring with an electron withdrawing substituent 
(para-chlorophenyl group) has been successfully prepared and characterized. 
This study has identified both the free ligand H2L and the Pt(II) complex [PtL] 
as having high antiproliferative activity since they are capable of not only circumvent 
cisplatin resistance in A2780cisR cells but they also exhibit high antiproliferative 
activity against breast (T-47D) cancer cells.  
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Table 1 Crystal data and structure refinement for [PdL]·DMSO and [PtL]·DMSO. 
 
 [PdL]·DMSO [PtL]·DMSO 
Molecular formula C25H25Cl2N7OPdS3 C25H25Cl2N7OPtS3 
Formula weight 713.00 801.69 
Temperature (K) 100(2) 100(2) 
Wavelength (Å) 0.71073 0.71073 
Crystal system Triclinic Triclinic 
Space group Pī Pī 
a(Å) 7.4630(5) 7.484(3) 
b(Å) 13.2509(7) 13.251(6) 
c(Å) 14.6594(9) 14.680(6) 
α/º 77.351(3) 76.611(14) 
β/º 87.513(3) 87.296(15) 
γ/º 81.522(3) 80.818(15)g 
Volume(Å
3
) 1398.96(15) 1398.0(10) 
Z 2 2 
Density (calculated) (g/cm
3
) 1.693 1.905 
Absorption coefficient (mm-
1
) 1.113 5.469 
F(000) 720 784 
Crystal size (mm3) 0.57 x 0.09 x 0.03 0.40 x 0.04 x 0.02 
Index ranges -8≤h≤8, -15≤k≤15, -17≤l≤17 -8≤h≤8, -15≤k≤15, -16≤l≤17 
Reflections collected 47797 15003 
Table 1
Independent reflections 5086  4672  
Data / restraints / parameters 5086 /0/356 4672 /0/356 
Goodness-of-fit on F2 1.066 1.002 
Final R indices [I>2σ(I)] R1 = 0.0380, wR2 = 0.1116 R1 = 0.0450, wR2 = 0.1074 
R indices (all data) R1 = 0.0498, wR2 = 0.1297 R1 = 0.0748, wR2 = 0.1409 
Largest diff. peak and hole, e.Å
-3
 1.126 and -0.783 1.606 and -2.739 
 
Table 2. Selected bond distances (Å) and angles (º) for [PdL]·DMSO and [PtL]·DMSO. 
 
[PdL]·DMSO                                                                  [PtL]·DMSO  
Bond lengths (Å)     
S(1)-C(8) 1.673(5)   S(1)-C(17) 1.804(10) 
S(2)-C(17) 1.779(4)   S(2)-C(10) 1.672(11) 
C(6)-N(2) 1.291(6)   C(2)-N(5) 1.299(14) 
C(8)-N(3) 1.389(6)   C(8)-N(2) 1.298(14) 
C(8)-N(4) 1.373(6)   C(10)-N(3) 1.424(14) 
C(9)-N(4) 1.406(6)   C(10)-N(4) 1.347(13) 
C(15)-N(5) 1.304(6)   C(11)-N(4) 1.421(13) 
C(17)-N(6) 1.297(6)   C(17)-N(6) 1.290(14) 
C(17)-N(7) 1.367(6)   C(17)-N(7) 1.348(14) 
C(18)-N(7) 1.402(6)   C(23)-N(7) 1.411(13) 
Pd(1)-N(1) 2.029(4)   Pt(1)-N(1) 2.017(9) 
Pd(1)-N(3) 2.044(4)   Pt(1)- N(3) 2.032(9) 
Pd(1)-N(5) 1.979(4)   Pt(1)- N(5) 1.985(9) 
Pd(1)-S(2) 2.2842(11)   Pt(1)-S(1) 2.279(3) 
      
Bond angles (º)     
N(1)-Pd(1)-N(3) 91.73(15)   N(1)-Pt(1)-N(3) 91.8(3) 
N(1)-Pd(1)-N(5) 80.58(15)   N(1)-Pt(1)-N(5) 80.5(4) 
N(3)-Pd(1)-S(2) 104.2(11)   N(3)-Pt(1)-S(2) 103.7(2) 
Table 2
N(5)-Pd(1)-S(2) 83.43(11)   N(5)-Pt(1)-S(2) 83.0(3) 
N(1)-Pd(1)-S(2) 163.95(11)   N(1)-Pt(1)-S(2) 164.5(3) 
N(3)-Pd(1)-N(5) 172.25(15)   N(3)-Pt(1)-N(5) 172.2(4) 
 
Table 3. In vitro antiproliferative activity of H2L, [PdL] and [PtL] complexes and H2L
2
, 
[PtL
2
] and cisplatin, evaluated in human T-47D (breast cancer), A2780 and A2780cisR 
(epithelial ovarian cancer) cell lines.  
The IC50 values are averages of two independent determinations. 
ND = not determined 
a
 Values taken from Ref. [23] 
 
  IC50±SD (µM)   
 
A2780 A2780cisR T-47D             RF  
IC50(A2780cisR)/IC50(A2780) 
        H2L
 7.16±0.14 13±1 7.42±0.14 1.8 
[PdL] 24±1 >100 >100 > 4.2 
[PtL] 7.12±0.21 9.13±0.07 9.17±0.07 1.3 
        H2L
2 >100
a 
>100
a ND --- 
[PtL
2
] 20±2
a 
18±1
a ND 1.1 
Cisplatin 0.88±0.01 7.77±0.10 12±1 8.8 
Table 3
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Fig. S1. MS spectrum for H2L 
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Fig. S2. 1NMR spectrum for H2L  
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 Fig. S3. 13C NMR spectrum for H2L 
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Fig. S4. MS spectrum for [PdL] 
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Fig. S5. 1NMR spectrum for [PdL] 
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Fig. S6. MS spectrum for [PtL] 
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Fig. S7. 
1NMR spectrum for [PtL] 
 
